Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › reslizumab

reslizumab

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of reslizumab

11 trials tracked of reslizumab: 8 in phase 3 or 4 and 7 with published results. The most-cited published study has 551 citations.

11Trials tracked
8Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 3 8 Phase 2 2 Phase 1 1
  1. Phase 3 Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Completed · 551 cited
  2. Phase 3 A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Completed · 425 cited
  3. Phase 3 Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Completed · 382 cited
  4. Phase 3 A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Completed · 88 cited
  5. Phase 3 A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed · 88 cited
  6. Phase 3 Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils Completed · 23 cited
Show 5 more trials
  1. Phase 3 An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils Completed · 23 cited
  2. Phase 3 Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis Completed
  3. Phase 2 Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis Completed
  4. Phase 2 Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma Completed
  5. Phase 1 Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists Completed

Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review evaluates anti-IL-5 and anti-IL-5Rα biologics for eosinophilic respiratory and systemic diseases
Allergy & Immunology Sys. Review
Systematic review evaluates anti-IL-5 and anti-IL-5Rα biologics for eosinophilic respiratory and systemic diseases New Asthma Drugs Target the Real Troublemakers Hiding in Your Lungs
This systematic review examined the use of anti-IL-5 and anti-IL-5Rα biologics in patients with severe eosinophilic asthma, chronic rhinosin…
New asthma drugs target the specific immune cells causing swelling and mucus in severe asthma, nasal polyps, and rare eosinophil diseases.
Frontiers Apr 16, 2026
Systematic review examines IL-5-targeted and multi-target therapies for eosinophil-associated diseases including asthma and COPD
Oncology Sys. Review
Systematic review examines IL-5-targeted and multi-target therapies for eosinophil-associated diseases including asthma and COPD A Tricky Immune Messenger Behind Severe Asthma
This systematic review evaluated IL-5-targeted therapies, multi-target combination therapies, bispecific antibodies, and small-molecule inhi…
A protein called IL-5 fuels severe asthma, but new drugs targeting multiple immune pathways at once may finally help patients who haven't re…
Frontiers Apr 14, 2026